All In Biotech

Drug Trial Radar · NCT04572152

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

Dec 7, 2020

Primary completion

May 2, 2023

Study completion Aug 31, 2023

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Oct 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH), Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Combination with AK104 in Subjects with Advanced or Metastatic Solid Tumors.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

  • AK119Biological

    Subjects will receive AK119 by intravenous administration.

  • AK104Biological

    On the same day subjects will receive AK104 by intravenous administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug
  2. Number of participants with a Dose Limiting Toxicity (DLT)Time frame: During the first 6 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Blacktown Cancer and Haematology Centre (Blacktown Hospital)

    Blacktown, New South Wales, Australia

  • ICON Cancer Centre

    South Brisbane, Queensland, Australia

  • Ashford Cancer Centre

    Adelaide, South Australia, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Alfred Health (The Alfred Hospital)

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.